Drug intelligence / Profile preview

ligilactobacillus salivarius PS11610

Development stage: Unknown
Lead developer: Zinereo Pharma
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Ligilactobacillus salivarius PS11610 is a specific probiotic strain developed by Zinereo Pharma and marketed under the brand name Fertibiome®. It is a biologic therapeutic classified as a live biotherapeutic product. The primary indication for this probiotic is infertility, particularly idiopathic (unknown) infertility, and to improve success rates for couples undergoing assisted reproductive treatments (ART) like in vitro fertilization (IVF). The mechanism of action involves modulating the urogenital microbiome and the local immune system to correct dysbiosis (an unhealthy microbial imbalance). The strain has demonstrated antimicrobial activity against various urogenital pathogens. Clinical studies have shown that supplementation with a daily dose of 1×10⁹ CFU can improve pregnancy, delivery, and live birth rates. [2] The European Food Safety Authority (EFSA) has granted Ligilactobacillus salivarius a Qualified Presumption of Safety (QPS) status.

Brand names: Fertibiome
Other names: Lactobacillus salivarius PS11610

Beyond the preview

Go deeper on ligilactobacillus salivarius PS11610.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ligilactobacillus salivarius PS11610.

Explore the full profile